keyword
MENU ▼
Read by QxMD icon Read
search

Pancreatic neuroendocrine

keyword
https://www.readbyqxmd.com/read/29691623/minimally-invasive-versus-open-treatment-for-benign-sporadic-insulinoma-comparison-of-short-term-and-long-term-outcomes
#1
Giulio Belfiori, Dominik Wiese, Stefano Partelli, Sabine Wächter, Elisabeth Maurer, Stefano Crippa, Massimo Falconi, Detlef K Bartsch
BACKGROUND: Benign insulinoma is the most common functioning neuroendocrine tumor of the pancreas, and its incidence is estimated at 0.4%. The treatment of choice is organ-preserving resection. The aim of this study was to compare short-term and long-term outcomes of minimally invasive laparoscopic or robotic enucleation (MIC-EN) and open enucleation (O-EN) for sporadic benign insulinoma. METHODS: A retrospective bi-institutional analysis of 71 patients who underwent an enucleation for sporadic benign insulinoma between 2003 and 2016 was performed...
April 24, 2018: World Journal of Surgery
https://www.readbyqxmd.com/read/29690667/-clinicopathologic-characterisitics-of-pancreatic-acinar-cell-carcinomas
#2
X H Ding, Z B Wang, X M Qiu
Objective: To investigate clinical, pathological and immunohistochemical features of pancreatic acinar cell carcinoma. Methods: A retrospective review of surgical and pathological databases between 2011 and 2016 at PLA General Hospital was collected and 14 cases of acinar cell carcinoma (ACC) of the pancreas were identified. EnVision immunohistochemistry was used to detect the expression of Trypsin, bcl-10 and cytokeratin(CK) proteins. Results: The patients included nine cases of pure ACC, 3 cases of mixed acinar ductal carcinoma, 1 case of mixed acinar-neuroendocrine carcinoma and acinar-ductal-neuroendocrine carcinoma, respectively...
April 8, 2018: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://www.readbyqxmd.com/read/29689572/endoscopic-ultrasound-elastography-of-small-solid-pancreatic-lesions-a-multicenter-study
#3
Andre Ignee, Christian Jenssen, Paolo G Arcidiacono, Michael Hocke, Kathleen Möller, Adrian Saftoiu, Uwe Will, Pietro Fusaroli, Julio Iglesias-Garcia, Ryan Ponnudurai, Maria C Petrone, Barbara Braden, Eike Burmester, Yi Dong, Nathan S Atkinson, Christoph F Dietrich
BACKGROUND:  The prevalence of malignancy in patients with small solid pancreatic lesions is low; however, early diagnosis is crucial for successful treatment of these cases. Therefore, a method to reliably distinguish between benign and malignant small solid pancreatic lesions would be highly desirable. We investigated the role of endoscopic ultrasound (EUS) elastography in this setting. METHODS:  Patients with solid pancreatic lesions ≤ 15 mm in size and a definite diagnosis were included...
April 24, 2018: Endoscopy
https://www.readbyqxmd.com/read/29684618/everolimus-is-a-new-anti-cancer-molecule-metabolic-side-effects-as-lipid-disorders-and-hyperglycemia
#4
REVIEW
L Morviducci, F Rota, L Rizza, P Di Giacinto, S Ramponi, M R Nardone, C Tubili, A Lenzi, P Zuppi, R Baldelli
In the last few years, molecular targeted therapies have replaced traditional cytotoxic chemotherapy in the fight against many cancers to the extent that our understanding of tumor biology has become more sophisticated. This shift has markedly changed adverse event profiles, compared to cytotoxic chemotherapy, affecting a diverse range of organ systems. Everolimus was approved by the FDA in 2011 for the treatment of progressive pancreatic NE tumors (Yao, 2011; Jensenn, 2012). It is an inhibitor of mammalian target of rapamycin (mTOR) and exhibits antitumor activity via disruption of various signaling pathways and it's used in the treatment of advanced renal cell cancer, breast cancer and neuroendocrine tumors (NET); it's used also as anti-rejection agent for transplantation but with lower doses for anti-rejection (1...
April 20, 2018: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/29683974/pancreatic-neuroendocrine-tumors-and-intraductal-papillary-mucinous-neoplasm-of-the-pancreas-a-systematic-review
#5
Alba Manuel-Vazquez, José Manuel Ramia, Raquel Latorre-Fragua, Ainhoa Valle-Rubio, Vladimir Arteaga-Peralta, Carmen Ramiro-Pérez, Roberto de la Plaza-Llamas
OBJECTIVES: This study aimed to identify factors that explain the association of intraductal papillary mucinous neoplasms-pancreatic neuroendocrine tumors (IPMNs-PNETs), radiological characteristics, and factors that might guide therapy. METHODS: We performed a systematic review of the literature to search for articles on concurrent IPMN-PNET, mixed endocrine-exocrine pancreatic tumors, and/or PNET with an intraductal growth pattern. RESULTS: A review of the literature suggests that there is some confusion about association of IPMNs-PNETs...
April 19, 2018: Pancreas
https://www.readbyqxmd.com/read/29675259/successful-neoadjuvant-peptide-receptor-radionuclide-therapy-for-an-inoperable-pancreatic-neuroendocrine-tumour
#6
Tiago Nunes da Silva, M L F van Velthuysen, Casper H J van Eijck, Jaap J Teunissen, J Hofland, Wouter W de Herder
Non-functional pancreatic neuroendocrine tumours (NETs) can present with advanced local or distant (metastatic) disease limiting the possibility of surgical cure. Several treatment options have been used in experimental neoadjuvant settings to improve the outcomes in such cases. Peptide receptor radionuclide therapy (PPRT) using beta emitting radiolabelled somatostatin analogues has been used in progressive pancreatic NETs. We report a 55-year-old female patient with a 12.8 cm pancreatic NET with significant local stomach and superior mesenteric vein compression and liver metastases...
2018: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/29668669/pancreatic-neuroendocrine-neoplasms-a-role-of-laparoscopy-in-surgical-treatment-review
#7
Jacek Szeliga, Marek Jackowski
Pancreatic neuroendocrine neoplasms (PNENs) are extremely rare neoplasms of the pancreas. They originate from pancreatic islet cells, and from the very beginning, cancer cells may or may not show hormone hypersecretion. Currently, surgical treatment is the only therapeutic method that significantly prolongs life expectancy, and in such cases it is a method of choice. In the paper, a review of literature based on the Medline database and including mainly the period of 2013 to 2017 was performed. In each case an operating surgeon is responsible for selection of a method used for surgical treatment...
April 17, 2018: Surgical Laparoscopy, Endoscopy & Percutaneous Techniques
https://www.readbyqxmd.com/read/29666945/carbonic-anhydrase-9-expression-in-well-differentiated-pancreatic-neuroendocrine-neoplasms-might-be-associated-with-aggressive-behavior-and-poor-survival
#8
Joo Young Kim, Sang Hwa Lee, Soyeon An, Sung Joo Kim, You-Na Sung, Ki-Byung Song, Dae Wook Hwang, Song Cheol Kim, Seung-Mo Hong
Well-differentiated pancreatic neuroendocrine neoplasms/tumors (PanNETs) are rare neoplasms with diverse clinical behavior. Biomarker discovery is important for predicting clinical course and prognosis of PanNET patients. Carbonic anhydrase 9 (CA9) and vimentin are hypoxia and epithelial-mesenchymal transition-related proteins of which expression in many carcinomas has been associated with poor prognosis, but their significance in PanNET has yet to be determined. We assessed CA9 and vimentin expression in 164 PanNETs and compared this with clinicopathologic characteristics...
April 18, 2018: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/29665210/endoscopic-ultrasound-diagnosis-of-merkel-cell-carcinoma-metastasizing-to-pancreas
#9
Juliana Pinho, Diana Montezuma, Paula Monteiro, Mário Dinis-Ribeiro, Pedro Bastos
Merkel cell carcinoma (MCC) is a rare and aggressive primary neuroendocrine tumor of the skin, with a high propensity for local, regional and distant spread1 . However, distant metastasis of MCC to the pancreas are rarely seen. EUS-FNA is an effective tool in the evaluation and differential diagnosis of pancreatic mass lesions3 . Differentiating metastatic pancreatic tumors, especially Merkel cell carcinoma, from primary pancreatic tumor will influence clinical management and therapeutic strategies2 . This article is protected by copyright...
April 17, 2018: Cytopathology: Official Journal of the British Society for Clinical Cytology
https://www.readbyqxmd.com/read/29655834/metformin-use-associates-with-longer-progression-free-survival-of-patients-with-diabetes-and-pancreatic-neuroendocrine-tumors-receiving-everolimus-and-or-somatostatin-analogues
#10
Sara Pusceddu, Claudio Vernieri, Massimo Di Maio, Riccardo Marconcini, Francesca Spada, Sara Massironi, Toni Ibrahim, Maria Pia Brizzi, Davide Campana, Antongiulio Faggiano, Dario Giuffrida, Maria Rinzivillo, Sara Cingarlini, Francesca Aroldi, Lorenzo Antonuzzo, Rossana Berardi, Laura Catena, Chiara De Divitiis, Paola Ermacora, Vittorio Perfetti, Annalisa Fontana, Paola Razzore, Carlo Carnaghi, Maria Vittoria Davì, Carolina Cauchi, Marilina Duro, Sergio Ricci, Nicola Fazio, Federica Cavalcoli, Alberto Bongiovanni, Anna La Salvia, Nicole Brighi, Annamaria Colao, Ivana Puliafito, Francesco Panzuto, Silvia Ortolani, Alberto Zaniboni, Francesco Di Costanzo, Mariangela Torniai, Emilio Bajetta, Salvatore Tafuto, Silvio Ken Garattini, Daniela Femia, Natalie Prinzi, Laura Concas, Giuseppe Lo Russo, Massimo Milione, Luca Giacomelli, Roberto Buzzoni, Gianfranco Delle Fave, Vincenzo Mazzaferro, Filippo de Braud
BACKGROUND & AIMS: Metformin seems to have anti-cancer effects. However, it is not clear whether use of glycemia and metformin affect outcomes of patients with advanced pancreatic neuroendocrine tumors (pNETs). We investigated the association between glycemia and progression-free survival (PFS) of patients with NETs treated with everolimus and/or somatostatin analogues, as well as the association between metformin use and PFS time. METHODS: We performed a retrospective analysis of 445 patients with advanced pNET treated at 24 medical centers in Italy, from 1999 through 2015...
April 12, 2018: Gastroenterology
https://www.readbyqxmd.com/read/29650928/-conversion-surgery-after-etoposide-cisplatin-ep-therapy-for-huge-pancreatic-neuroendocrine-carcinoma-a-case-report
#11
Akiko Nakazawa, Tetsuya Mitsui, Yoichi Miyata, Riki Ninomiya, Masahiko Komagome, Akira Maki, Fumiaki Ozawa, Yoshifumi Beck
Neuroendocrine carcinoma(NEC)is known as rapid tumor growth, high grade malignancy and poor prognosis. We report a case of huge pancreatic NEC successfully performed conversion surgery after EP therapy. A 70-year-old female, was presented to our hospital with appetite loss. CT scan revealed huge tumor, 15 cm in diameter, locating at the pancreas with possible involvement to liver, stomach, common hepatic artery, left gastric artery and gastroduodenal artery. Peritoneal dissemination and para-aortic lymph node metastasis were also suspected...
March 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29649302/identifying-tumor-in-pancreatic-neuroendocrine-neoplasms-from-ki67-images-using-transfer-learning
#12
Muhammad Khalid Khan Niazi, Thomas Erol Tavolara, Vidya Arole, Douglas J Hartman, Liron Pantanowitz, Metin N Gurcan
The World Health Organization (WHO) has clear guidelines regarding the use of Ki67 index in defining the proliferative rate and assigning grade for pancreatic neuroendocrine tumor (NET). WHO mandates the quantification of Ki67 index by counting at least 500 positive tumor cells in a hotspot. Unfortunately, Ki67 antibody may stain both tumor and non-tumor cells as positive depending on the phase of the cell cycle. Likewise, the counter stain labels both tumor and non-tumor as negative. This non-specific nature of Ki67 stain and counter stain therefore hinders the exact quantification of Ki67 index...
2018: PloS One
https://www.readbyqxmd.com/read/29629846/molecular-profiling-of-pancreatic-neuroendocrine-tumors-pnets-and-the-clinical-potential
#13
Massimiliano Camilli, Konstantinos Papadimitrio, Amanda Nogueira, Lorena Incorvaia, Antonio Galvano, Federica D'Antonio, Jose Ferri, Daniele Santini, Nicola Silvestris, Antonio Russo, Marc Peeters, Christian Rolfo
Pancreatic neuroendocrine tumors (pNETs) represent a small part of pancreatic neoplasms, and the knowledge about their indolent clinical course remains a subject of investigation. They occur sporadically or as part of familial cancer syndromes and are classified by WHO in 3 categories. There is ongoing research to understand their molecular profiling and leading mutations. Areas covered: The aim of this review is to clarify the overall aspects of tumorigenesis, to expose the latest developments in understanding the course of the disease and the possible therapeutic implications of these...
April 9, 2018: Expert Review of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29629321/laparoscopic-distal-pancreatectomy-for-neuroendocrine-tumors-of-the-pancreas
#14
In Gun Hyun, Yoo-Seok Yoon, Ho-Seong Han, Jai Young Cho, YoungRok Choi, Sungho Kim, Kil Hwan Kim
The incidence of incidentally discovered nonfunctioning pancreatic neuroendocrine tumors (PNETs) is increasing because of the widespread use of radiologic imaging studies. Due to their mostly small size, PNETs in the body and tail of the pancreas are suited for laparoscopic surgery. This video described our technique of laparoscopic distal pancreatectomy with and without preservation of spleen and splenic vessels for PNET. The decision on preservation of spleen and splenic vessels was made according to the relative location of tumors to the splenic vessels...
February 2018: Gland Surgery
https://www.readbyqxmd.com/read/29629320/combined-associating-liver-partition-and-portal-vein-ligation-for-staged-hepatectomy-alpps-followed-by-left-trisectionectomy-and-whipple-operation-for-pnet
#15
Ren Ji, Shi Zuo, Siyuan Qiu, Ping Li, Albert Chan, William Sharr, Chung Mau Lo
Pancreatic neuroendocrine tumor (PNET) is slow-growing, and account only for 2% of all pancreatic primary tumors. Surgical resection is still the only curative treatment for PNET patients. Unfortunately, most of PNETs was found with unresectable multiple liver metastases and extrahepatic metastasis as their characteristics of non-functional and asymptomatic. With advances in liver surgery in these years, especially combined associating liver partition and portal vein ligation for staged hepatectomy (ALPPS), provide a new curative surgical treatment for PNET with liver metastases patient...
February 2018: Gland Surgery
https://www.readbyqxmd.com/read/29629319/liver-transplantation-for-unresectable-pancreatic-neuroendocrine-tumors-with-liver-metastases-in-an-era-of-transplant-oncology
#16
REVIEW
Keita Shimata, Yasuhiko Sugawara, Taizo Hibi
Patients with pancreatic neuroendocrine tumors (pNETs) very often present with a metastatic disease at the first diagnosis. Liver transplantation (LT) for unresectable pNET with liver metastases (pNETLM) has been described to prolong survival in highly selected patients, although outcomes were worse than those of patients who underwent LT for gastrointestinal NETLM (GI-NETLM). In this review, several proposed criteria are described with their rationale and controversies. Most of the data used to establish these criteria do not reflect the recent improvements of non-surgical treatments that has changed the landscape of treatment for pNETs, including the development of peptide receptor radionuclide therapy and molecular-targeted agents (sunitinib and everolimus)...
February 2018: Gland Surgery
https://www.readbyqxmd.com/read/29629318/role-of-surgery-in-pancreatic-neuroendocrine-tumor
#17
REVIEW
Kai Pun Wong, Julian Shun Tsang, Brian Hung-Hin Lang
Pancreatic neuroendocrine tumours (PNETs) are rare. They are generally accepted to be slow-growing and have an indolent course. These tumours can be non-functioning or functioning, consisting of a biochemically heterogeneous group of tumours including insulinomas, gastrinomas, carcinoids and glucagonomas. Although surgery remains the mainstay of treatment, controversy still exists especially for non-functioning tumours <2 cm in size. Whether these should be resected or undergo intensive surveillance remains unclear...
February 2018: Gland Surgery
https://www.readbyqxmd.com/read/29629316/management-of-functional-neuroendocrine-tumors-of-the-pancreas
#18
REVIEW
Kjell Öberg
Pancreatic neuroendocrine tumors (pNETs) constitute a heterogenous group of malignancies with varying clinical presentation, tumor biology and prognosis. The incidence of pNETs has steadily increased during the last decades with an estimated incidence 2012 of 4.8/100,000. Recent whole genome sequencing of pNETs has demonstrated mutations in the DNA repair genes MUTYH and point mutations and gene fusions in four main pathways from chromatin remodeling, DNA damage repair, activation of mechanistic target of rapamycin (mTOR) signaling and the telomere maintenance...
February 2018: Gland Surgery
https://www.readbyqxmd.com/read/29629315/surgical-resection-of-neuroendocrine-tumors-of-the-pancreas-pnets-by-minimally-invasive-surgery-the-laparoscopic-approach
#19
REVIEW
Tomoki Shirota, Yuichi Nagakawa, Yatsuka Sahara, Chie Takishita, Yosuke Hijikata, Yuichi Hosokawa, Tetsushi Nakajima, Hiroaki Osakabe, Kenji Katsumata, Akihiko Tsuchida
Neuroendocrine tumors of the pancreas (pNETs) are a rare group of neoplasms that originate from the endocrine portion of the pancreas. Tumors that either secrete or do not secrete compounds, resulting in symptoms, can be classified as functioning and non-functioning pNETs, respectively. The prevalence of such tumors has recently increased due to the use of more sensitive imaging techniques, such as multidetector computed tomography, magnetic resonance imaging and endoscopic ultrasound. The biological behavior of pNETs varies widely from indolent, well-differentiated tumors to those that are far more aggressive...
February 2018: Gland Surgery
https://www.readbyqxmd.com/read/29629314/surgical-resection-of-pancreatic-neuroendocrine-neoplasm-by-minimally-invasive-surgery-the-robotic-approach
#20
REVIEW
Roxanne Y A Teo, Brian K P Goh
Over the past decade, there has been increasing adoption of minimally invasive pancreatic surgery world-wide and this has naturally expanded to the management of pancreatic neuroendocrine neoplasms (PNENs). More recently, robotic pancreatic surgery (RPS) was introduced to overcome the limitations during laparoscopic pancreatic surgery (LPS). Due to the relative rarity of PNEN and the novelty of minimally invasive pancreatic surgery in particular RPS today, the evidence for robotic surgery in PNENs remains extremely limited...
February 2018: Gland Surgery
keyword
keyword
5478
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"